Literature DB >> 26840570

Public health clinic-based hepatitis C testing and linkage to care in Baltimore.

O Falade-Nwulia1,2, S H Mehta3, J Lasola1, C Latkin3, A Niculescu1,2, C O'Connor3, P Chaulk2,3, K Ghanem1, K R Page1,2, M S Sulkowski1, D L Thomas1.   

Abstract

Testing and linkage to care are important determinants of hepatitis C virus (HCV) treatment effectiveness. Public health clinics serve populations at high risk of HCV. We investigated their potential to serve as sites for HCV testing, initiation of and linkage to HCV care. Cross-sectional study of patients accessing sexually transmitted infection (STI) care at the Baltimore City Health Department (BCHD) STI clinics, from June 2013 through April 2014 was conducted. Logistic regression was used to assess factors associated with HCV infection and specialist linkage to care. Between 24 June 2013 and 15 April 2014, 2681 patients were screened for HCV infection. Overall, 189 (7%) were anti-HCV positive, of whom 185 (98%) received follow-up HCV RNA testing, with 155 (84%) testing RNA positive. Of 155 RNA-positive individuals, 138 (89%) returned to the STI clinic for HCV RNA results and initial HCV care including counselling regarding transmission and harm reduction in alcohol, and 132 (85%) were referred to a specialist for HCV care. With provision of patient navigation services, 81 (52%) attended an offsite HCV specialist appointment. Alcohol use and lack of insurance coverage were associated with lower rates of specialist linkage (OR 0.4 [95% CI 0.1-0.9] and OR 0.4 [95% CI 0.1-0.9], respectively). We identified a high prevalence of HCV infection in BCHD STI clinics. With availability of patient navigation services, a large proportion of HCV-infected patients linked to off-site specialist care.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  HCV treatment; Implementation science; hazardous alcohol consumption; rapid testing; sexually transmitted infections clinic

Mesh:

Year:  2016        PMID: 26840570      PMCID: PMC4836954          DOI: 10.1111/jvh.12507

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  36 in total

Review 1.  Is there an association between alcohol consumption and sexually transmitted diseases? A systematic review.

Authors:  Robert L Cook; Duncan B Clark
Journal:  Sex Transm Dis       Date:  2005-03       Impact factor: 2.830

2.  Mental and physical symptoms associated with lower social support for patients with hepatitis C.

Authors:  Julie A Blasiole; Laura Shinkunas; Douglas R Labrecque; Robert M Arnold; Susan L Zickmund
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

3.  Patients attending STD clinics in an evolving health care environment. Demographics, insurance coverage, preferences for STD services, and STD morbidity.

Authors:  C L Celum; G Bolan; M Krone; K Code; P Leone; C Spaulding; K Henry; P Clarke; M Smith; E W Hook
Journal:  Sex Transm Dis       Date:  1997-11       Impact factor: 2.830

4.  Barriers to the treatment of hepatitis C. Patient, provider, and system factors.

Authors:  James A Morrill; Melissa Shrestha; Richard W Grant
Journal:  J Gen Intern Med       Date:  2005-08       Impact factor: 5.128

5.  The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Authors:  Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

6.  Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

Authors:  F Pessione; F Degos; P Marcellin; V Duchatelle; C Njapoum; M Martinot-Peignoux; C Degott; D Valla; S Erlinger; B Rueff
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

7.  Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II.

Authors:  J B Saunders; O G Aasland; T F Babor; J R de la Fuente; M Grant
Journal:  Addiction       Date:  1993-06       Impact factor: 6.526

8.  Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases.

Authors:  D L Thomas; R O Cannon; C N Shapiro; E W Hook; M J Alter; T C Quinn
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

9.  Integrating viral hepatitis prevention services into an urban STD clinic: Denver, Colorado.

Authors:  Julie Subiadur; Jennie L Harris; Cornelis A Rietmeijer
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

10.  Integrating viral hepatitis prevention into STD clinics in Illinois (excluding Chicago), 1999-2005.

Authors:  Richard Zimmerman; Carol Finley; Charlie Rabins; Karen McMahon
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

View more
  33 in total

1.  Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).

Authors:  S S Solomon; M S Sulkowski; P Amrose; A K Srikrishnan; A M McFall; B Ramasamy; M S Kumar; S Anand; D L Thomas; S H Mehta
Journal:  J Viral Hepat       Date:  2017-08-14       Impact factor: 3.728

2.  Monitoring the hepatitis C care cascade using administrative claims data.

Authors:  Cheryl Isenhour; Susan Hariri; Claudia Vellozzi
Journal:  Am J Manag Care       Date:  2018-05       Impact factor: 2.229

3.  Reply to MacDonald et al.

Authors:  Eshan U Patel; Shruti H Mehta; Denali Boon; Thomas C Quinn; David L Thomas; Aaron A R Tobian
Journal:  Clin Infect Dis       Date:  2020-01-16       Impact factor: 9.079

4.  Race and Hepatitis C Care Continuum in an Underserved Birth Cohort.

Authors:  Nicole J Kim; Cameron J Locke; Helen Park; Catherine Magee; Peter Bacchetti; Mandana Khalili
Journal:  J Gen Intern Med       Date:  2018-09-20       Impact factor: 5.128

5.  Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore.

Authors:  Oluwaseun Falade-Nwulia; Risha Irvin; Alana Merkow; Mark Sulkowski; Alexander Niculescu; Yngvild Olsen; Kenneth Stoller; David L Thomas; Carl Latkin; Shruti H Mehta
Journal:  J Subst Abuse Treat       Date:  2019-01-30

6.  Strategies for Expanding Access to HBV and HCV Testing and Care in the United States: The CDC Hepatitis Testing and Linkage to Care Initiative, 2012-2014.

Authors:  John W Ward
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

Review 7.  Direct-acting antiviral agents for HCV infection affecting people who inject drugs.

Authors:  Jason Grebely; Behzad Hajarizadeh; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

8.  The Hepatitis C Virus Care Continuum: Linkage to Hepatitis C Virus Care and Treatment Among Patients at an Urban Health Network, Philadelphia, PA.

Authors:  Catelyn Coyle; Anne C Moorman; Tyler Bartholomew; Gary Klein; Helena Kwakwa; Shruti H Mehta; Deborah Holtzman
Journal:  Hepatology       Date:  2019-03-26       Impact factor: 17.425

Review 9.  Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.

Authors:  Emma Day; Margaret Hellard; Carla Treloar; Julie Bruneau; Natasha K Martin; Anne Øvrehus; Olav Dalgard; Andrew Lloyd; John Dillon; Matt Hickman; Jude Byrne; Alain Litwin; Mojca Maticic; Philip Bruggmann; Havard Midgard; Brianna Norton; Stacey Trooskin; Jeffrey V Lazarus; Jason Grebely
Journal:  Liver Int       Date:  2018-09-22       Impact factor: 5.828

10.  Improving support and education of low-income baby boomers diagnosed with chronic hepatitis C virus infection through universal screening.

Authors:  Barbara J Turner; Kathryn Craig; Vidhi S Makanji; Bertha E Flores; Ludivina Hernandez
Journal:  J Clin Nurs       Date:  2017-05-23       Impact factor: 3.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.